CCCS invites feedback over merger concerns on PAH deals

Singapore

THE Competition and Consumer Commission of Singapore (CCCS) is inviting public feedback on the two-year commitments proposed by Pathology Asia Holdings (PAH) to address competition concerns in its planned merger of two private clinical laboratories.

PAH, a unit of private equity giant TPG Capital Asia, intends to integrate the businesses of the two labs - Innovative Diagnostics and Quest Laboratories - after acquiring them last year.